Straits Times Index
3,410.81 -29.07 (-0.85%) Nikkei
40,912.37 -1.28 (-0.00%) Hang Seng
17,799.61 -228.67 (-1.27%) FTSE 100
8,203.93 -37.33 (-0.45%) Bitcoin USD
56,699.42 +1,443.27 (+2.61%) CMC Crypto 200
1,180.48 -28.21 (-2.33%)
Mesoblast Limited (MESO)
After hours:
| Previous close | 6.80 |
| Open | 7.35 |
| Bid | 7.74 x 100 |
| Ask | 7.79 x 400 |
| Day's range | 7.25 - 7.86 |
| 52-week range | 1.61 - 10.24 |
| Volume | |
| Avg. volume | 266,317 |
| Market cap | 883.32M |
| Beta (5Y monthly) | 2.45 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.93 |
| Earnings date | 29 Jul 2024 - 02 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.00 |
ZacksMesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates
Mesoblast (MESO) skyrockets 208.2% year to date on encouraging progress with its pipeline candidates.
GlobeNewswireMesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its Biologics License Application (BLA) for approval of Ryoncil® (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD) with the U.S. Food and Drug Administration (FDA) next week. About Mesoblast Mesoblast (the Company) is a world leader in developi
Simply Wall St.ASX Growth Companies With High Insider Ownership To Watch In June 2024
As the ASX200 shows signs of a positive shift, buoyed by favorable movements in international markets and anticipation around the RBA's interest rate decision, investors are keenly watching for opportunities. In this environment, growth companies with high insider ownership on the ASX stand out as potentially strong candidates due to their aligned interests between management and shareholders.
